We have identified an antigen recognized on a human melanoma by autologous cytolytic T lymphocytes. It
When blood lymphocytes or tumor-infiltrating lymphocytes of melanoma patients are stimulated in vitro with irradiated tumor cells of the same patient, they often proliferate to produce populations of cytolytic T lymphocytes (CTLs) that show specificity for the tumor cells. From such autologous responder cell populations, it is possible to derive stable anti-tumor CTL clones.
Several antigens recognized by such anti-tumor CTL clones have been identified by an approach based on gene transfection and recognition of the transfectants by the CTLs. So far, two main categories of antigens have been found on human melanomas. The first group contains antigens encoded by genes, such as MAGE1, MAGE3, BAGE, and GAGE, that are not expressed in normal tissues except for testis but are expressed in a significant proportion of tumors of various histological types (1) (2) (3) (4) (5) (6) . The second group contains differentiation antigens encoded by genes that are expressed only in melanocytes and melanomas, such as tyrosinase, Melan-AMART-1, gplooPmell7, and gp75 (7) (8) (9) (10) (11) (12) (13) (14) . A third category of antigens could also be expected to be present on human tumors; namely, those caused by point mutations. We have observed in mouse tumor systems that point mutations can generate potent antigens recognized by syngeneic T lymphocytes (15) (16) (17) . Recently, a mouse tumor antigen recognized on Lewis lung carcinoma cells has been shown to result from a mutation in the connexin gene (18) . We have carried out a systematic study of the antigens recognized by autologous CTLs on melanoma LB33-MEL. Two cell lines, LB33-MEL.A and LB33-MEL.B, were derived from metastases that were removed from patient LB33 in 1988 and 1993, respectively (19) . A large number of CTL clones directed against LB33-MEL.A were obtained with blood lymphocytes collected from the patient in 1990. By selecting in vitro for resistance to lysis by some of these CTL clones, we obtained antigen-loss variants of LB33-MEL.A. These variants were resistant to various subsets of the panel of CTL clones, leading to the definition of five antigens on LB33-MEL.A. Remarkably, we observed that cell line LB33-MEL.B had lost the expression of the HLA class I molecules that presented these five antigens, suggesting that T-cell-mediated immune selection against the tumor cells bearing these antigens had occurred in vivo. We report here the identification of one of these antigens, named LB33-B. It is produced as a result of a point mutation.
MATERIALS AND METHODS
Cell Lines. Melanoma cell line LB33-MEL.A was derived from a cutaneous metastasis of patient LB33, and clone LB33-MEL.A-1 was obtained by limiting dilution (19) . We have obtained and described (19) (19) . All the LB33-MEL clonal cell lines were cultured in Iscove's medium (GIBCO) containing 10% (vol/vol) fetal calf serum (GIBCO), supplemented with L-arginine (116 mg/ml), L-asparagine (36 mg/ml), and Lglutamine (216 mg/ml). Human choriocarcinoma cell line JAR, which does not express major histocompatibility complex class I molecules (20) , was obtained from the American Type Culture Collection. The class I-negative human B-cell line ClR (21) , transfected with an HLA-B*4402 cDNA (22) , was provided by K. Fleischhauer (Istituto Scientifico H.S. Rafaele, Milan).
Lysis Test and CTL Stimulation Assay. Lytic activity of CTLs was tested in a 4-h chromium release assay. COS-7 transfectants were tested for their ability to stimulate the production of tumor necrosis factor by the CTL as described (23) . Briefly, 3000 CTLs were added to microwells containing the transfected cells. After 24 h, supernatants were collected and the tumor necrosis factor content of these supernatants was determined by testing their cytotoxic effect on WEHI164c13 cells (24) in a colorimetric assay (23) .
Construction of the cDNA Library and Transfection of COS-7 Cells. The cDNA library was constructed basically as described (9 (27) . GenBank accession numbers of cDNA clones 350/2, 475/1, and 122/3 are U20908, U20897, and U20896, respectively.
PCR Assay for the Presence of the Mutated MUM-1 Allele. We used the amplification refractory mutation system PCR methodology that relies on the perfect nucleotide match needed at the 3' end of primers to ensure specificity of DNA amplifications (28) . DNA extracted from various cells as indicated in Fig. 4 (Fig. 2B) .
The sequence of cDNA 350/2 showed no significant similarity to any sequence recorded in data banks (GenBank/ EMBL, July 7, 1995 coding for a peptide with Glu in position 2 and Phe in position 9 or 10, the recently identified HLA-B44 binding motif (22) . Only one such sequence was found (namely, nonapeptide (Fig. 3A) . isoleucine at position 5 of the antigenic peptide. A competition assay indicated that the normal and the mutated peptides bind with a similar affinity to the HLA-B44 molecule (Fig. 3B ), but the peptide encoded by the normal sequence was not recognized by the anti-B CTLs (Fig. 3A) . This suggests that the isoleucine generated by the point mutation is an essential part of the epitope recognized by anti-tumor CTL 159/5. We propose the provisional name MUM-1 (melanoma ubiquitous mutated) for the gene encoding antigen LB33-B. To test cells for the presence of the normal or the mutated MUM-1 sequence, we used PCR primers with 3'-end nucleotides corresponding to either the normal or the mutated nucleotide. The normal sequence was found in the DNA of all the normal and tumor cells that were tested, including LB33 melanoma cells, 15 melanoma lines of other patients, blood mononuclear cells, and EBV-transformed B cells from patient LB33 (Fig. 4) . The mutated sequence was found only in the two melanoma cell lines of patient LB33. It was also found in a tumor sample from this patient, indicating that the mutation did not occur in vitro.
Part Remarkably, the sequence encoding the antigenic peptide straddles the junction between the end of exon 2 and the following intron and the point mutation that generates the antigen is located in position 6 of the intron. It is followed immediately by a stop codon, suggesting that the peptide derives from the C terminus of the translation product of an incompletely spliced mRNA.
Reverse transcription and PCR amplification revealed the presence of MUM-1 RNA spliced for introns 1 and 2 in all normal and tumor tissue samples tested. The MUM-1 RNA species containing intron 2 was also found to be ubiquitous. These results suggest that the lack of splicing of intron 2 is independent of the point mutation and that the specificity of the antigen for tumor LB33-MEL is caused by the mutation and not by a splicing difference.
F stP .tg tag GTT TTG GCC CGA ACC GCG ACT TCA ACA AAA AAT AAG AGA AGA AAG GAA TAT TTT CTA GCT GTG CAA ATC CTC TCC CTA GAG GAA AAg tta att gtt gtg ttg ttt taa tac.. (15) (16) (17) . In some instances, an amino acid change transforms a peptide that is incapable of binding to a class I molecule into a peptide that binds well. In other instances, the peptide encoded by the normal sequence already binds, but because the gene is expressed in normal tissues, the T lymphocytes that recognize the antigen are presumably eliminated or anergized and this results in natural tolerance. Here, the amino acid change produces a peptide with a new epitope that can be recognized by a fresh set of T lymphocytes. The tumor antigen encoded by the mutated MUM-1 gene belongs to the second category.
To our knowledge, this is the first instance where human CTLs obtained by stimulation with autologous tumor cells have been shown to recognize an antigen generated by a point mutation. The possibility that genes such as ras or p53, which are often mutated in human tumors, might produce antigens recognized by human T lymphocytes has been carefully examined (31, 32) . Stimulation by cells incubated with mutated ras or p53 peptides produced human CD8+ lymphocytes that responded specifically to the mutated peptides. But no evidence was obtained that these lymphocytes recognize cells expressing the mutated ras or p53 genes.
Some point mutations found in the genome of tumor cells may be irrelevant to the transformation of the tumor. They may arise because carcinogens that induce the mutation responsible for the transformation also produce irrelevant mutations. The loss of enzymes that correct replication errors is frequently observed in tumors, and it should also contribute to this phenomenon (33) (34) (35) . Because the point mutation that generates an antigen on melanoma LB33-MEL is absent from any of the other tumors tested, it is possible that it represents one of these irrelevant mutations. Antigens such as LB33-B may accordingly be of limited use for cancer immunotherapy, since they can be used only to immunize the patient in whom they have been discovered. One the other hand, such antigens resulting from point mutations ought to be absolutely specific for the tumor, and technical progress may make the identification of such antigens so easy that treatment of patients bearing tumors with such individually specific tumor antigens will become feasible.
Our observation that the translation of some intronic regions can produce antigenic peptides extends the possible range of the surveillance of the integrity of the genome by T lymphocytes.
